Ming De Biotech: Stock May Be Subject to Delisting Risk Warning

NightAirdropper · 2026-03-22T11:35:19+00:00

Mingde Biotech expects a profit loss in 2025 and may face delisting risk warning. The company expects net loss of 15 million to 25 million yuan, non-GAAP net loss of 100 million to 140 million yuan, and operating revenue between 237 million to 297 million yuan.

NightAirdropper

2026-03-22 11:35:19

Abstract generation in progress

Mingde Bio (002932.SZ) announced on March 22nd that the company expects a total loss of 50 million to 75 million yuan in 2025, a net loss of 15 million to 25 million yuan, and a non-recurring net loss of 100 million to 140 million yuan. The revenue after deducting non-recurring items is projected to be between 237 million and 297 million yuan. Due to negative net profit and revenue after deductions below 300 million yuan, the company’s stock may be subject to delisting risk warning (*ST) after the 2025 annual report is disclosed. The annual report audit is still ongoing, and final data will be based on the audited annual report.

Daily Economic News

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes